Skip to main content

Table 4 Adjust of demographic factors for CKD

From: Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways

Variate

CKD (3 to 5 stages)

CKD (4 and 5 stages)

CKD (3 stage)

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

KA

0.701 (0.276–1.783)

0.4556

0.115 (0.021–0.639)

0.0134

0.490 (0.086–2.806)

0.4230

Gender

1.155 (0.324–4.122)

0.8243

1.631 (0.174–15.291)

0.6684

0.807 (0.069–9.486)

0.8645

Age

0.958 (0.919–0.999)

0.0456

0.914 (0.856–0.976)

0.0069

0.988 (0.926–1.055)

0.7200

Complication

0.394 (0.109–1.421)

0.1547

0.272 (0.032–2.318)

0.2338

0.656 (0.110–3.903)

0.6429

Smoke

1.221 (0.534–2.794)

0.6363

4.069 (1.073–15.436)

0.0391

0.538 (0.175–1.654)

0.2793

Alcohol

1.192 (0.249–5.691)

0.8261

0.048 (0.001–1.744)

0.0976

11.172 (0.878–142.131)

0.0629

Education

0.473 (0.203–1.099)

0.0818

0.478 (0.108–2.120)

0.3313

0.288 (0.057–1.462)

0.1331

Occupation

1.363 (0.708–2.625)

0.3547

2.231 (0.847–5.876)

0.1043

1.264 (0.371–4.309)

0.7084

  1. Italic values indicate significance of p < 0.05